Mamatha Gaddam

Assistant Professor

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

COM | Internal Med Hem-Onc

4 h-index 21 pubs 68 cited

Research Areas

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Mamatha Gaddam, Assistant Professor in Internal Medicine's Hematology-Oncology division at the University of Arkansas for Medical Sciences, investigates the clinical presentation, outcomes, and management of immune effector cell-associated hemophagocytic lymphohistiocytosis (HLH) syndrome, particularly in the context of chimeric antigen receptor (CAR-T) cell therapy. Her work also examines immune checkpoint inhibitor toxicity in older cancer patients and explores therapeutic advances in myelodysplastic syndromes. Gaddam has published on the impact of the CAR-T era on survival in diffuse large B-cell lymphoma and the real-world survival outcomes of CAR-T and bispecific T-cell engagers in relapsed/refractory DLBCL. She has also investigated the prediction of survival based on drug-induced rash after mogamulizumab administration in mycosis fungoides/sezary syndrome and literature insights into hyperhemolysis in sickle cell disease. Gaddam holds an h-index of 4 with 19 total publications and 59 citations. She collaborates with researchers at her institution, including Ankur Varma, Alan Baltz, Bhavesh Mohan Lal, and Nishanth Thalambedu.

Metrics

h-index: 4
Publications: 21
Citations: 68

Selected Publications

Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

DOI OpenAlex
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)

DOI OpenAlex
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)

DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

4 citations DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

3 citations DOI OpenAlex
Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting (2024)

DOI OpenAlex
Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)

DOI OpenAlex
Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy (2024)

DOI OpenAlex
Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021) (2024)

DOI OpenAlex
Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023)

DOI OpenAlex
Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity (2023)

25 citations DOI OpenAlex